CA2809966C - Treatment for cocaine addiction - Google Patents

Treatment for cocaine addiction Download PDF

Info

Publication number
CA2809966C
CA2809966C CA2809966A CA2809966A CA2809966C CA 2809966 C CA2809966 C CA 2809966C CA 2809966 A CA2809966 A CA 2809966A CA 2809966 A CA2809966 A CA 2809966A CA 2809966 C CA2809966 C CA 2809966C
Authority
CA
Canada
Prior art keywords
disulfiram
use according
composition
selegiline
cocaine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2809966A
Other languages
English (en)
French (fr)
Other versions
CA2809966A1 (en
Inventor
Seth Lederman
Herbert Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tonix Pharmaceuticals Inc
Original Assignee
Tonix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharmaceuticals Inc filed Critical Tonix Pharmaceuticals Inc
Publication of CA2809966A1 publication Critical patent/CA2809966A1/en
Application granted granted Critical
Publication of CA2809966C publication Critical patent/CA2809966C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA2809966A 2010-09-01 2011-08-31 Treatment for cocaine addiction Expired - Fee Related CA2809966C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37909510P 2010-09-01 2010-09-01
US61/379,095 2010-09-01
PCT/US2011/001529 WO2012050594A1 (en) 2010-09-01 2011-08-31 Treatment for cocaine addiction

Publications (2)

Publication Number Publication Date
CA2809966A1 CA2809966A1 (en) 2012-04-19
CA2809966C true CA2809966C (en) 2019-01-08

Family

ID=45938591

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2809966A Expired - Fee Related CA2809966C (en) 2010-09-01 2011-08-31 Treatment for cocaine addiction

Country Status (9)

Country Link
US (1) US20130165511A1 (enExample)
EP (2) EP3170499A1 (enExample)
JP (1) JP6355921B2 (enExample)
KR (1) KR20130132774A (enExample)
AU (3) AU2011314358B2 (enExample)
CA (1) CA2809966C (enExample)
DK (1) DK2611440T3 (enExample)
PT (1) PT2611440T (enExample)
WO (1) WO2012050594A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037281T2 (hu) * 2009-11-20 2018-08-28 Tonix Pharma Holdings Ltd Eljárás és készítmény poszt-traumás stressz rendellenesség tüneteinek kezelésére ciklobenzaprin alkalmazásával
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
US9636408B2 (en) 2013-03-15 2017-05-02 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
CA2961822A1 (en) 2014-09-18 2016-03-24 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride
BR112020011345A2 (pt) 2017-12-11 2020-11-17 Tonix Pharma Holdings Limited tratamento com ciclobenzaprina para agitação, psicose e declínio cognitivo na demência e condições neurodegenerativas
CN113811358A (zh) 2019-03-26 2021-12-17 通尼克斯制药控股有限公司 S-(n,n-二乙基氨基甲酰基)谷胱甘肽的盐形式
US11724486B2 (en) * 2019-07-09 2023-08-15 Kyndryl, Inc. Printing customized medication based on current user data and medical records of the user

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155584A (en) 1962-12-03 1964-11-03 Abbott Lab Compositions and method of inhibiting monoamine oxidase and treating hypertension
SE404186B (sv) 1975-06-09 1978-09-25 Astra Laekemedel Ab Forfarande for framstellning av cyklopropanolderivat
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
WO1992021333A2 (en) 1991-05-24 1992-12-10 Pharmavene, Inc. Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
US5204369A (en) 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
BR9501972A (pt) 1995-05-09 1997-08-26 Tostes Luiz Roberto Mallat Composição farmacêutica metodo para tratamento de dependência ou abuso de álcool e método para tratamento de distúrbios psiquiátricos geneticamente relacionados ao alcoolismo
CN1116870C (zh) 1996-03-15 2003-08-06 萨默塞特药品有限公司 司立吉林在制备用于预防或治疗外周神经病的药物中的应用
US6255497B1 (en) 1997-04-29 2001-07-03 The Endowment For Research In Human Biology, Inc. Method for the inhibition of ALDH-I useful in the treatment of alcohol dependence or alcohol abuse
CA2308453A1 (en) 1997-10-28 1999-05-06 Schering Corporation Method of reducing craving in mammals
AU3899199A (en) 1998-05-12 1999-11-29 Endowment for Research in Human Biology, Inc., The Methods and assays useful in the treatment of alcohol dependence or alcohol abuse
FR2788982B1 (fr) 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
AU2002348135A1 (en) * 2001-10-31 2003-05-12 Recovery Pharmaceuticals, Inc. Methods for the treatment of addiction
EP1441708B1 (en) * 2001-11-05 2009-04-08 Krele Pharmaceuticals LLC Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
CA2414500A1 (en) * 2002-12-17 2004-06-17 Purepharm Inc. Agonist-aversive combination medicines
US20080078382A1 (en) * 2006-09-20 2008-04-03 Lemahieu Edward Methods and Systems of Delivering Medication Via Inhalation

Also Published As

Publication number Publication date
PT2611440T (pt) 2017-04-26
CA2809966A1 (en) 2012-04-19
DK2611440T3 (en) 2017-05-15
AU2011314358B2 (en) 2016-07-07
AU2018204813A1 (en) 2018-07-19
AU2016238908B2 (en) 2018-04-05
EP3170499A1 (en) 2017-05-24
WO2012050594A1 (en) 2012-04-19
KR20130132774A (ko) 2013-12-05
JP2013536837A (ja) 2013-09-26
US20130165511A1 (en) 2013-06-27
EP2611440A4 (en) 2014-02-19
EP2611440A1 (en) 2013-07-10
EP2611440B1 (en) 2017-02-01
JP6355921B2 (ja) 2018-07-11
AU2016238908A1 (en) 2016-10-20
AU2011314358A1 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
AU2016238908B2 (en) Treatment for cocaine addiction
US8481599B2 (en) Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
JP4097285B2 (ja) 種々の頑固な疾患の治療のための医薬の製造に有用な組成物
CA2467356C (en) Selective norepinephrine serotonin reuptake inhibitors for treating fibromyalgia syndrome, chronic fatigue syndrome and pain
US20020019421A1 (en) Compositions and therapy for substance addiction
MXPA02001568A (es) Ciclobenzaprina para tratar trastornos de ansiedad generalizada y composiciones de la misma.
WO2001034172A2 (en) Methods and compositions for treating reward deficiency syndrome
AU2002354017A1 (en) Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
TW202506129A (zh) 維貝隆（ｖｉｂｅｇｒｏｎ）用於治療膀胱過動症之用途
WO2010112530A1 (en) Pipamperone and a second agent in treating mood and anxiety disorders
HK1186661B (en) Treatment for cocaine addiction
HK1186661A (en) Treatment for cocaine addiction
ZA200005301B (en) New drug combinations of a N.A.R.I., preferably reboxetine, and pindolol.
Dean Illicit drugs and drug interactions
JP2005306882A (ja) 感情的不安定の治療のための医薬の製造に有用な組成物
JP4372723B2 (ja) 慢性疼痛の治療のための医薬の製造に有用な組成物
Reddy Drug Therapy for the Management of Attention Deficit-Hyperactivity Disorder
CA2338330A1 (en) Use of moclobemide for treating certain phsychiatric and medical disorders
MXPA00010945A (en) New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol
HK1087643A (en) Compositions comprising dextromethorphan and quinidine or quinine for the treatment of emotional lability

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160822

MKLA Lapsed

Effective date: 20200831